EASL Press Conference 2019 Upload video: No flash player has been set up. Please select a player to play Flash videos.
13Apr, 19ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression bILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with...
30May, 20MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infectionsCommittee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive...
15Mar, 12Press Release, Moscow, March 15th, 2012Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program Co-Invests with Germany’s Public/Private...
10Mar, 14Press Release, Moscow, March 11th, 2014MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF...
30Sep, 14Press Release, Moscow, October, 2014Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry...
